Project detail - ACON INJECTABLE INVESTORS I, L.P.

ACON INJECTABLE INVESTORS I, L.P.

Back to map

Who is our client

FMO’s investment in ACON Injectable Investors I, L.P. is used for further investment into Vitalis Group. Established in 1999, Vitalis Group is a leading manufacturer and distributor of generic injectable pharmaceuticals with production facilities in Colombia and Mexico, and sales to more than 20 countries, primarily in Latin America. The Group’s products are mainly used in surgical theaters, emergency rooms and intensive care units, and cover multiple therapeutic areas such as antibiotics, anesthesia, gastroenterology, oncology, and cardiology, among others.

Funding objective

FMO's investment will be used to acquire the companies that comprise Vitalis Group, and to support its growth plans in order to contribute to the stability, growth and innovation of the domestic health care systems in Colombia and Mexico.

Why we fund this project

This investment supports the deepening of local production capacity in Colombia and Mexico, and sales of essential medicines into Latin America, contributing to SDG3 (good health). Vitalis Group currently provides skilled labor opportunities to more than 1200 staff and is expected to add another 150 jobs over the next 5 years, in line with FMO’s aim to contribute to SDG8 (decent work and economic growth). Two thirds of the workforce are female employees, supporting SDG5 (gender equality).

Environmental and social rationale

The E&S category is B+

Region
Latin America & The Caribbean
Country
Latin America & The Caribbean
Sector
Infrastructure, Manufacturing and Services
Signing date
5/17/2021
Total FMO financing
USD 19.68 MLN
Fund
FMO
Risk categorization on environmental and social impacts, A = high risk, B+ = medium high risk, B = medium risk, C = low risk Environmental & Social Category
(A, B+, B or C)
B+